Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7.

PMID:
22067397
2.

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

Mita MM, Gong J, Chawla SP.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):465-82. doi: 10.1586/17512433.2013.827397. Epub 2013 Aug 23. Review. Erratum in: Expert Rev Clin Pharmacol. 2013 Nov;6(6):732.

PMID:
23971829
3.

A role for maintenance therapy in managing sarcoma.

Ray-Coquard I, Le Cesne A.

Cancer Treat Rev. 2012 Aug;38(5):368-78. doi: 10.1016/j.ctrv.2011.07.003. Epub 2011 Aug 16. Review.

PMID:
21843915
4.

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.

Dancey JE, Monzon J.

Future Oncol. 2011 Jul;7(7):827-39. doi: 10.2217/fon.11.57. Review.

PMID:
21732754
5.

Everolimus in renal cell carcinoma.

Wang Y.

Drugs Today (Barc). 2010 Aug;46(8):557-66. doi: 10.1358/dot.2010.46.8.1516824. Review.

PMID:
20830316
6.

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.

Chmielowski B, Federman N, Tap WD.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1217-28. doi: 10.1586/era.12.100. Review.

PMID:
23098121
7.

Current phase II clinical data for ridaforolimus in cancer.

Spreafico A, Mackay HJ.

Expert Opin Investig Drugs. 2013 Nov;22(11):1485-93. doi: 10.1517/13543784.2013.831404. Epub 2013 Aug 21. Review.

PMID:
23964772
8.

Mammalian target of rapamycin inhibitors in sarcomas.

Okuno S.

Curr Opin Oncol. 2006 Jul;18(4):360-2. Review.

PMID:
16721131
9.

Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.

Silk AW, Schuetze SM.

Curr Treat Options Oncol. 2012 Sep;13(3):285-98. doi: 10.1007/s11864-012-0194-4. Review.

PMID:
22610342
10.

The role of mTOR inhibitors for treatment of sarcomas.

Mita MM, Tolcher AW.

Curr Oncol Rep. 2007 Jul;9(4):316-22. Review.

PMID:
17588357
11.

Ridaforolimus.

[No authors listed]

Drugs R D. 2010;10(3):165-78. doi: 10.2165/11586010-000000000-00000. Review.

12.

New therapeutic strategies for soft tissue sarcomas.

von Mehren M.

Curr Treat Options Oncol. 2003 Dec;4(6):441-51. Review.

PMID:
14585225
13.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
14.

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M.

Target Oncol. 2011 Mar;6(1):29-39. doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28. Review.

PMID:
21533543
15.

Pazopanib in the treatment of soft tissue sarcoma.

Schöffski P.

Expert Rev Anticancer Ther. 2012 Jun;12(6):711-23. doi: 10.1586/era.12.41. Review.

PMID:
22716487
16.

ET-743: the US experience in sarcomas of soft tissues.

Demetri GD.

Anticancer Drugs. 2002 May;13 Suppl 1:S7-9. Review.

PMID:
12173492
17.

The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.

Ryan CW, Desai J.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e386. Review.

18.

Updating progress in sarcoma therapy with mTOR inhibitors.

Blay JY.

Ann Oncol. 2011 Feb;22(2):280-7. doi: 10.1093/annonc/mdq307. Epub 2010 Jun 29. Review.

PMID:
20591820
19.

Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

Versleijen-Jonkers YM, Vlenterie M, van de Luijtgaarden AC, van der Graaf WT.

Crit Rev Oncol Hematol. 2014 Aug;91(2):172-85. doi: 10.1016/j.critrevonc.2014.02.001. Epub 2014 Feb 15. Review.

PMID:
24613529
20.

Phase 1 clinical trials for sarcomas: the cutting edge.

Subbiah V, Kurzrock R.

Curr Opin Oncol. 2011 Jul;23(4):352-60. doi: 10.1097/CCO.0b013e3283477a94. Review.

PMID:
21519259

Supplemental Content

Support Center